Santhera Pharmaceuticals has decided to discontinue its Phase III SIDEROS trial of Puldysa (idebenone) in patients with Duchenne muscular dystrophy (DMD).

The move comes after an independent Data and Safety Monitoring Board (DSMB) reviewed interim data and found that the trial is not likely to meet its primary goal.

During the interim analysis, the DSMB reviewed the efficacy of the drug candidate in DMD patients who are in respiratory decline and on concomitant glucocorticoid treatment.

The primary endpoint was the change of forced vital capacity percentage predicted (FVC%p) from baseline to 18 months of treatment.

With the interim data showing narrow probability in meeting the primary endpoint at the end of the study, DSMB advised discontinuing the trial citing its futility. Data did not reveal any safety concerns.

After the discontinuation of the trial, enrolled participants will stop taking study medication and complete the  follow-up assessments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company intends to analyse the impact of discontinuation on current expanded access programmes with relevant regulatory agencies.

The data prompted Santhera to plan a restructuring, shifting its focus on another DMD drug candidate vamorolone and execute on its other pipeline programmes.

Santhera will also withdraw the European marketing authorisation application and halt the global development of Puldysa.

Santhera Pharmaceuticals CEO Dario Eklund said: “While this is obviously not the outcome we expected, all our efforts in DMD will now be focused on progressing the promising drug candidate vamorolone which we recently licensed from ReveraGen to its next inflection point, the readout of six-month top-line data from the pivotal VISION-DMD study planned for the second quarter of 2021.”

Apart from progressing vamorolone, Santhera also plans to focus on lonodelestat for cystic fibrosis and other lung diseases, along with its discovery-stage gene therapy method for congenital muscular dystrophy.